Paysign (PAYS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual meeting scheduled for May 8, 2026, to elect seven directors and ratify Baker Tilly US, LLP as independent auditor for 2026.
Proxy materials and annual report for 2025 made available online; voting encouraged via internet, mail, or in person.
Record date for voting is March 9, 2026, with 55,185,394 shares outstanding; quorum requires over 50% of shares.
Directors and executive officers control 21.6% of voting shares.
Voting matters and shareholder proposals
Shareholders will vote on electing seven director nominees and ratifying Baker Tilly US, LLP as auditor.
Board recommends voting FOR all director nominees and auditor ratification.
Shareholder proposals for the 2027 meeting must be submitted by November 30, 2026, for inclusion in proxy materials.
Voting results will be reported on Form 8-K within four business days after the meeting.
Board of directors and corporate governance
Board consists of seven members; four are independent per Nasdaq standards.
CEO also serves as Chairman; Board believes this structure aligns strategy and accountability.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.
Board and committees met regularly in 2025; all directors attended at least 75% of meetings.
Code of Ethics and Insider Trading Policy in place; annual questionnaires required for conflict disclosure.
Latest events from Paysign
- Achieved 40.5% revenue growth and 107% EBITDA growth, with balanced dual-engine expansion.PAYS
Corporate presentation - Record revenue, margin expansion, and raised outlook driven by pharma and plasma growth.PAYS
Q2 2026 - FY2025 revenue up 40.5% to $82M; FY2026 guidance $106.5M–$110.5M, balanced by plasma and pharma.PAYS
Planet MicroCap Las Vegas 2026 - FY2025 saw 40.5% revenue growth and a shift to balanced plasma and pharma revenue streams.PAYS
16th Annual East Coast IDEAS Conference - FY2025 saw 40.5% revenue growth and expanding margins, with balanced plasma and pharma momentum.PAYS
Conference presentation - Revenue up 50.8% and net income more than doubled, with strong margin expansion in Q1 2026.PAYS
Q1 2026 - Annual meeting to elect seven directors and ratify auditor set for May 8, 2026.PAYS
Proxy filing - 2025 saw 40.5% revenue growth and margin expansion, with 2026 guidance projecting 30–35% growth.PAYS
Q4 2025 - Rapid growth in patient affordability and tech-driven margin expansion offset plasma headwinds.PAYS
The MicroCap Rodeo Conference - NYC